CRVS Corvus Pharmaceuticals Inc

Price (delayed)

$11.72

Market cap

$985.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.52

Enterprise value

$946.27M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 8

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells ...

Highlights
The debt has contracted by 28% YoY and by 11% from the previous quarter
The EPS has shrunk by 174% QoQ but it has increased by 16% YoY
Corvus Pharmaceuticals's net income has shrunk by 189% QoQ and by 7% YoY

Key stats

What are the main financial stats of CRVS

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
1.03%
1 week
-6.24%
1 month
-26.84%
1 year
212.53%
YTD
52.21%
QTD
-19.89%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.93M
Net income
-$44.17M
Gross margin
N/A
Net margin
N/A
Corvus Pharmaceuticals's net income has shrunk by 189% QoQ and by 7% YoY
The operating income has dropped by 54% year-on-year and by 12% since the previous quarter

Price vs fundamentals

How does CRVS's price correlate with its fundamentals

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has shrunk by 174% QoQ but it has increased by 16% YoY
The price to book (P/B) is 38% lower than the last 4 quarters average of 6.5 and 6% lower than the 5-year quarterly average of 4.3

Efficiency

How efficient is Corvus Pharmaceuticals business performance
Corvus Pharmaceuticals's return on invested capital has shrunk by 76% QoQ but it has surged by 69% YoY
The company's return on assets has shrunk by 76% QoQ but it rose by 46% YoY
The ROE has dropped by 67% since the previous quarter but it has soared by 66% year-on-year

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
Corvus Pharmaceuticals's total liabilities has increased by 26% QoQ and by 24% YoY
The debt is 100% less than the equity
The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
The debt has contracted by 28% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.